{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:11:28Z","timestamp":1760735488672,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejca.2021.01.003","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T05:56:17Z","timestamp":1613368577000},"page":"185-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A letter of response to comments on\u00a0\u2018A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy\u00a0for advanced peritoneal metastases of gastrointestinal tract cancers\u2019"],"prefix":"10.1016","volume":"147","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Dumont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-2450","authenticated-orcid":false,"given":"Christophe","family":"Passot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.01.003_bib1","unstructured":"Rovers KP, Lurvink RJ, Deenen MJ, de Hingh IHJT. PIPAC-oxaliplatin for peritoneal metastases of gastrointestinal cancers. Eur J Cancer. Letter to editor."},{"key":"10.1016\/j.ejca.2021.01.003_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","article-title":"BIG-RENAPE Networks. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers","volume":"140","author":"Dumont","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.003_bib3","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1248\/bpb.b17-00400","article-title":"Factors influencing the appearance of oxaliplatin-induced allergy","volume":"40","author":"Nishihara","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ejca.2021.01.003_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/0959-8049(95)00140-E","article-title":"Role of leucovorin dosing and administration schedule","volume":"31","author":"Jolivet","year":"1995","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.003_bib5","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.bjc.6600185","article-title":"Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity","volume":"86","author":"Fischel","year":"2002","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.01.003_bib6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2021.01.003_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.01.003_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","article-title":"Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis","volume":"254","author":"Quenet","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2021.01.003_bib9","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","article-title":"Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC):the RENAPE study","volume":"25","author":"Malgras","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2021.01.003_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1055-3207(03)00051-6","article-title":"Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis","volume":"12","author":"Elias","year":"2003","journal-title":"Surg Oncol Clin"},{"key":"10.1016\/j.ejca.2021.01.003_bib11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/codi.13130","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis","volume":"18","author":"Demtr\u00f6der","year":"2016","journal-title":"Colorectal Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:27Z","timestamp":1760733087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":11,"alternative-id":["S0959804921000137"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A letter of response to comments on\u00a0\u2018A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy\u00a0for advanced peritoneal metastases of gastrointestinal tract cancers\u2019","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.09.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}